1. Introduction {#sec1-cancers-12-02049}
===============

Tumor protein p53 (*TP53*) is a multifunctional tumor suppressor gene that is intimately involved in the control of target genes that regulate "healthy" biological processes, including cell-cycle arrest, apoptosis, senescence, energy metabolism, and antioxidant defense to prevent tumorigenesis \[[@B1-cancers-12-02049]\]. In recent years, several experimental and clinical studies have also indicated a role for *TP53* in the control of tumor angiogenesis \[[@B2-cancers-12-02049]\]. This effect seems to be linked to cross-talk mechanisms between *TP53*, vascular endothelial growth factor (VEGF), and VEGF receptors.

A highly conserved and functional p53-binding site has been identified within the *VEGF* promoter and the p53 tumor suppressor downregulates VEGF expression \[[@B3-cancers-12-02049]\]. Loss of *TP53* in tumor cells enhances HIF-1alpha levels and augments HIF-1-dependent transcriptional activation of the *VEGF* gene in response to hypoxia \[[@B4-cancers-12-02049]\]. *TP53*-deficient cancer cells were found to produce reactive oxygen species, which activated fibroblasts to mediate angiogenesis by VEGF both in-vivo and in-vitro \[[@B5-cancers-12-02049]\]. The transcription factor E2F1 showed regulation of angiogenic activity via p53-dependent transcriptional control of VEGF expression \[[@B6-cancers-12-02049]\]. In experimental models, mutant *TP53* can up-regulate the transcription of VEGF receptor 2 (VEGFR2) by promoter remodeling \[[@B7-cancers-12-02049]\]. These molecular mechanisms may explain analyses of human cancer tissues that have reported significant increases in VEGF expression levels in the presence of *TP53* mutations \[[@B8-cancers-12-02049],[@B9-cancers-12-02049],[@B10-cancers-12-02049]\]. Interestingly, in a large pan-cancer study \[[@B9-cancers-12-02049]\], the association between VEGF up-regulation and *TP53* mutants remained independent of *HIF-1* and *MDM2* overexpression. This translational background explains recent clinical findings in advanced cancer patients who had improved responses and survival outcomes after VEGF/VEGF receptor (VEGFR) inhibitor therapy mostly in tumors harboring a *TP53* mutation \[[@B11-cancers-12-02049],[@B12-cancers-12-02049],[@B13-cancers-12-02049],[@B14-cancers-12-02049],[@B15-cancers-12-02049]\].

The concept that *TP53* alterations may represent a favorable biomarker for treating patients with anti-angiogenesis agents contrasts with previous findings from standard chemotherapy studies, where *TP53* dysregulation was generally associated with poor clinical outcomes \[[@B16-cancers-12-02049]\]. However, this is not surprising considering the multiple and widespread roles of *TP53* and the prevalence of p53-associated mechanisms of chemoresistance \[[@B16-cancers-12-02049]\].

Despite decades of research, the analysis of the *TP53* status for predictive purposes in cancer therapy has not been implemented in routine clinical practice yet. Major limitations concern the lack of standardized methods for defining the *TP53* status in tumor samples. Mutational analysis is more reliable than immunohistochemistry in solid tumors, but somatic *TP53* mutations cannot be considered a homogeneous group inducing an on/off effect \[[@B1-cancers-12-02049]\]. The majority of *TP53* mutations occurring in human solid neoplasms are missense mutations with a large gradient of functional consequences \[[@B1-cancers-12-02049]\]. Missense *TP53* mutations can be classified for clinical purposes by considering the residual transcriptional activity score (*TP53~RTAS~*) \[[@B17-cancers-12-02049]\], derived from the results of a site-directed mutagenesis technique and yeast-based functional assay \[[@B18-cancers-12-02049]\].

Gastric cancer ranks among the most frequently *TP53*-mutated solid tumors \[[@B19-cancers-12-02049]\], and in recent years, the anti-VEGFR2 inhibitor Ramucirumab coupled with Paclitaxel has become standard second-line systemic therapy in this lethal disease \[[@B20-cancers-12-02049]\]. Unfortunately, the magnitude and the duration of the survival gain in Ramucirumab/Paclitaxel treated patients are limited and the discovery of predictive markers would improve the selection of patients and allow the adoption of novel combination therapies \[[@B21-cancers-12-02049]\].

This background prompted us to plan a translational study in patients with metastatic gastric cancer treated with Ramucirumab/Paclitaxel including the analysis of *TP53* mutations and *TP53~RTAS~* in their tumor samples. The association between the mutant *TP53* functional status and survival outcome was assessed and overall patient survival was the primary endpoint of the study. To better characterize the predictive impact of *TP53* mutations, an additional retrospective cohort of patients treated with standard chemotherapy for advanced disease was included in the study.

2. Results {#sec2-cancers-12-02049}
==========

The overall study population consisted of 110 gastric cancer patients whose primary tumors were analyzed for *TP53* mutations. The study group included 48 cases who underwent second-line Ramucirumab/Paclitaxel. In the control group, 62 patients were treated with standard first-line chemotherapy with a 5-Fluorouracil and a platinum compound (Cisplatin or Oxaliplatin).

2.1. TP53 Analysis in Primary Gastric Tumors {#sec2dot1-cancers-12-02049}
--------------------------------------------

As shown in [Table 1](#cancers-12-02049-t001){ref-type="table"}, 61 *TP53* mutations were detected in total, including 47 missense mutations (77%), 7 nonsense mutations (11.4%), 4 frameshift mutations (6.6%), 2 splice site mutations (3.3%), and 1 in-frame deletion (1.7%). Some "hot-spot" missense mutations occurred in more than one patient: p.R282W and p.G244D in two cases, p.R283H in three cases, p.R273C in five cases. Four patients showed a combination of two or more *TP53* mutations in their tumor samples. Overall, 70 out of 110 patients showed tumor samples positive for *TP53* mutations (63.6%). The distribution of *TP53* mutations (any type) according to clinical and pathological characteristics of patients and tumors is shown in [Table 2](#cancers-12-02049-t002){ref-type="table"}. No significant association was found except for a prevalence of *TP53* mutations in intestinal-type gastric cancer according to Lauren's classification ([Table 2](#cancers-12-02049-t002){ref-type="table"}).

2.2. Classification of TP53 Mutations and Study Groups {#sec2dot2-cancers-12-02049}
------------------------------------------------------

Results of the residual transcriptional activity score (RTAS) analysis for missense mutations (*TP53~RTAS~*) are listed in [Table 1](#cancers-12-02049-t001){ref-type="table"}. *TP53~Inactive~* missense mutations were found in 10 patients in the Ramucirumab/Paclitaxel group and 11 patients in the chemotherapy control group. The remaining 49 *TP53* mutation-positive patients were classified as carriers of a *TP53~Active~* missense mutation and carriers of non-missense mutations (nonsense, frameshift, splice-site, and in-frame deletions). *TP53~Active~* missense mutation carriers were in 13 cases in the Ramucirumab/Paclitaxel group and 25 cases in the chemotherapy control group. Non-missense mutations carriers totaled 5 in the Ramucirumab/Paclitaxel group and 6 in the chemotherapy control group.

2.3. Ramucirumab/Paclitaxel Second-Line Therapy and TP53 Analysis {#sec2dot3-cancers-12-02049}
-----------------------------------------------------------------

In the 48 patients of the study group, the results of the second-line therapy showed a 20.8% overall response rate (10 patients with a partial response) and a median overall survival (OS) time of 8.4 months (5--8.8 months 95% CI). No significant association was detected between *TP53* mutations and tumor response. Partial responses occurred in three patients with *TP53~Inactive~* missense mutations, in two patients with *TP53* non-missense mutations, and in five patients with wild-type *TP53~RTAS~* status.

Median OS times were: 9.5 months (9.0--10.7 months 95% CI) in carriers of *TP53~Inactive~* missense mutations; 8.6 months (5.9--9.9 months 95% CI) in carriers of other *TP53* mutations; 6.0 months (3.2--8.5 months 95% CI) in carriers of *TP53~Active~* missense mutations; 4.5 months (4.1--8.2 months 95% CI) in patients without *TP53* mutations. A significant difference was observed between the survival curves of the four groups using the log--rank test ([Figure 1](#cancers-12-02049-f001){ref-type="fig"}). The analysis of hazard ratios with 95% CIs indicates the survival advantage of carriers of *TP53~Inactive~* missense mutations over other groups except for carriers of other *TP53* mutations ([Figure 1](#cancers-12-02049-f001){ref-type="fig"}). The favorable effect of the *TP53~Inactive~* mutational status was retained in the multivariate model ([Figure 2](#cancers-12-02049-f002){ref-type="fig"}).

2.4. Standard First-Line Chemotherapy and TP53 Analysis {#sec2dot4-cancers-12-02049}
-------------------------------------------------------

In the 62 patients of the control group, the results of the first-line chemotherapy showed a 51.6% overall response rate (28 partial responses and 4 complete responses). The median OS time was 9 months (95% Cls = 8--10.2 months). No significant association was detected between *TP53* mutations and tumor response. Partial responses occurred in 5 patients (45%) with *TP53~Inactive~* missense mutations, in 13 patients (52%) with *TP53~Active~* missense mutations, in 2 patients (40%) with *TP53* non-missense mutations, and in 8 patients (38%) without *TP53* mutations. Complete responses were observed in one patient in each of the four groups. Median OS times were: 8 months (4.3--9.0 months 95% CI) in carriers of *TP53~Inactive~* missense mutations; 8 months (8.4--14.7 months 95% CI) in carriers of other *TP53* mutations; 8.5 months (5.7--10 months 95% CI) in carriers of *TP53~Active~* missense mutations; 10.6 months (8.4--14.7 months 95% CI) in patients without *TP53* mutations. A comparison of the survival curves using the log--rank test showed significant differences between the four groups ([Figure 3](#cancers-12-02049-f003){ref-type="fig"}).

The analysis of hazard ratios with 95% CIs reveals a detrimental effect of the *TP53~Inactive~* missense mutations status in comparison to patients without *TP53* mutations ([Figure 3](#cancers-12-02049-f003){ref-type="fig"}). The adverse effect of the *TP53~Inactive~* mutational status was retained in the multivariate model ([Figure 2](#cancers-12-02049-f002){ref-type="fig"}).

2.5. VEGF/VEGFR Analysis and TP53 Mutational Status in Gastric Cancer Tissues {#sec2dot5-cancers-12-02049}
-----------------------------------------------------------------------------

Since Ramucirumab is a VEGFR2 antagonist that blocks the binding of VEGF-A, VEGF-C, and VEGF-D, we analyzed the mRNA expression and copy number alterations of these genes in gastric adenocarcinomas. *VEGF-A* gene gain was significantly more frequent in tumors with *TP53~Inactive~* mutations (58.1%) as compared to tumors with *TP53~Active~* mutations (35.7%) or wild-type p53 (13.4%) (*p* = 0.019 and *p* \< 0.0001, respectively). Importantly, *VEGF-A* mRNA expression was correspondingly higher in the *TP53~Inactive~* group as compared to tumors with *TP53~Active~* or wild-type p53 (*p* = 0.047 and *p* = 0.0039, respectively). While no differences in the gene loss of *VEGF-A* were observed between these groups, the deletion of *VEGF-C* and *VEGFR2* occurred less often in the wild-type p53 group as compared to the *TP53* mutation subgroups (*p* \< 0.01 and *p* \< 0.0001, respectively), although this did not translate to significant differences in mRNA expression levels. Loss of *VEGF-D* occurred most frequently in the *TP53~Inactive~* group (32.6%), with significantly fewer deletion events in wild-type p53 tumors (*p* \< 0.0001), however, there were no differences in mRNA expression levels ([Figure 4](#cancers-12-02049-f004){ref-type="fig"}). Together, these findings support a mechanism exclusive to tumors with transcriptionally inactive p53 mutants, indicating a reliance on increased VEGF-A production to drive tumorigenesis.

3. Discussion {#sec3-cancers-12-02049}
=============

The results of this study support the hypothesis that *TP53* may be a valuable biomarker that can identify metastatic gastric cancer patients with the greatest benefit from an anti-angiogenic, anti-VEGFR2 systemic therapy. Importantly, the positive therapeutic effect, being associated with a specific group of transcriptionally inactive *TP53* missense mutations (*TP53~RTAS~* \< 1%) would simplify the development of a genetic test for further investigations, and hopefully, for routine clinical practice. This finding contributes to a mounting body of evidence linking *TP53* mutational status to anti-angiogenic treatment clinical outcomes in patients with advanced cancers \[[@B11-cancers-12-02049],[@B12-cancers-12-02049],[@B13-cancers-12-02049],[@B14-cancers-12-02049],[@B15-cancers-12-02049]\].

So far, the loss of function of the *TP53* tumor suppressor gene has been considered an unfavorable prognostic feature in patients with solid tumors \[[@B22-cancers-12-02049]\]. Uncontrolled cell-cycle regulation, senescence, metabolism, and apoptosis in *TP53* "null" neoplasms may explain this association \[[@B22-cancers-12-02049]\]. However, the clinical impact of *TP53* dysregulation may vary in patients undergoing anti-cancer systemic therapies, which could depend on differences in the mechanisms of action of anti-cancer agents \[[@B16-cancers-12-02049]\]. Pre-clinical and translational studies have found links between *TP53* loss of function and resistance to DNA damaging agents like platinum compounds and anthracyclines \[[@B16-cancers-12-02049]\]. Conversely, tumors with loss of normal *TP53* function may be even more sensitive to anti-cancer agents like Paclitaxel that stabilizes tubulin polymerization resulting in the arrest of mitosis and the induction of *TP53*-independent apoptosis \[[@B23-cancers-12-02049],[@B24-cancers-12-02049]\]. It has been also demonstrated that Paclitaxel, especially in fractionated regimens, exploits anti-angiogenic mechanisms of action \[[@B25-cancers-12-02049]\] Together, these chemotherapy-related aspects, in addition to pre-clinical and clinical studies linking *TP53* mutations to the VEGF pathway \[[@B5-cancers-12-02049],[@B6-cancers-12-02049],[@B7-cancers-12-02049],[@B8-cancers-12-02049]\] and anti-VEGF/VEGFR systemic therapies \[[@B9-cancers-12-02049],[@B10-cancers-12-02049],[@B11-cancers-12-02049],[@B12-cancers-12-02049],[@B13-cancers-12-02049],[@B14-cancers-12-02049],[@B15-cancers-12-02049]\], contribute to explaining the favorable results of the Ramucirumab/Paclitaxel combination in metastatic gastric cancers harboring *TP53* mutations.

In the present study, we performed a combined analysis of *TP53~RTAS~* missense mutations and VEGF-A and VEGFR2 expression levels in gastric adenocarcinoma tumor tissue samples. The results indicate a significant VEGF-A up-regulation in tumor samples with *TP53~Inactive~* and unmodified VEGFR2 expression. These results parallel findings in previous analyses \[[@B3-cancers-12-02049],[@B4-cancers-12-02049],[@B5-cancers-12-02049],[@B6-cancers-12-02049],[@B7-cancers-12-02049]\]. In a large pan-cancer cohort of 7525 samples, Li AM et al. \[[@B9-cancers-12-02049]\] demonstrated up-regulated VEGF-A transcript levels in tumors with *TP53* mutations, particularly in adenocarcinomas, regardless of their organ of origin, while VEGFR2 expression levels were not significantly modified by *TP53* mutational status or reduced in squamous carcinomas. Since VEGF-A is considered the most potent angiogenic ligand and it exhibits the highest binding affinity for VEGFR2 \[[@B26-cancers-12-02049]\], it is plausible that VEGF-A up-regulation is a major mechanism underlying the positive clinical impact of *TP53* mutants on anti-VEGF/VEGFR2 therapies.

Intriguingly, additional mechanisms may also explain the positive clinical interaction between chemotherapy, anti-angiogenics, and *TP53* status. In a translational analysis from a randomized trial in endometrial cancer, a remarkable survival benefit was found in the bevacizumab/chemotherapy arm in the presence of *TP53* mutations causing loss of function or "null" phenotype \[[@B14-cancers-12-02049]\]. Results from cell models suggested a mechanism of synthetic lethality derived from the effects of agents like bevacizumab to abrogate cell cycle checkpoints in the absence of p53 by blocking signaling downstream of tyrosine kinases \[[@B14-cancers-12-02049]\]. This causes the premature entry of cancer cells into vulnerable phases of the cell cycle where chemotherapy agents are most effective.

The majority of somatic *TP53* mutations detected in human cancers are missense mutations \[[@B1-cancers-12-02049],[@B2-cancers-12-02049]\]. These mutations, which arise from a point mutation in a single nucleotide, can result in amino acid changes that can lead to highly variable degrees of functional consequences. For example, an amino acid may be replaced by another amino acid with very similar chemical properties, resulting in a protein that still functions normally. In contrast, some amino acid changes may cause greater dysfunction or non-functional protein products. To overcome difficulties in the interpretation of *TP53* mutational analysis, we adopted a functional classification of *TP53* missense mutations based on a transcriptional activity score as the result of a site-directed mutagenesis technique and yeast-based functional assay \[[@B17-cancers-12-02049],[@B18-cancers-12-02049]\]. Tumors harboring *TP53~Inactive~* missense mutations showed the longest survival time and the greatest benefit from the anti-VEGFR2 Ramucirumab/Paclitaxel systemic therapy. The analysis of survival curves suggests that tumors with *TP53* non-missense mutations may also obtain some survival benefit from Ramucirumab/Paclitaxel (non-significant 52% risk reduction in the comparison with the wild-type group). Notably, *TP53* non-missense mutants producing the loss of the protein product do not display specific properties of some missense mutations (i.e., hotspot mutants) with augmented oncogenic potential. This effect may be caused by their capacity to impair the wild-type allele (dominant-negative effects) and/or by specific gain-of-function effects \[[@B25-cancers-12-02049],[@B26-cancers-12-02049]\]. Many missense *TP53* mutants are expressed as stable proteins that exert dominant-negative effects by interfering with the remaining wild-type p53 protein copies through the formation of hetero-tetramers. A "prion-like" effect of some p53 mutants has also been shown to inactive wild-type p53 in vitro by forcing the wild-type protein to adopt a denatured, mutant-like conformation \[[@B2-cancers-12-02049],[@B27-cancers-12-02049]\]. As a result of the gain-of-function effect, some *TP53* missense mutants were found to promote tumor angiogenic pathways, whereas *TP53* deletion or truncating events did not \[[@B28-cancers-12-02049],[@B29-cancers-12-02049]\].

Our analysis of *TP53* mutations in relation to the clinical characteristics and pathological features of gastric adenocarcinomas in the present study population is supported by pivotal studies on the molecular classification of gastric cancer \[[@B30-cancers-12-02049]\]. *TP53* mutations characterize the most common of four molecular subtypes of gastric adenocarcinomas, defined by chromosomal instability. This genomically unstable subtype is associated with an intestinal histotype according to Lauren's classification, and a homogenous distribution along the different gastric sites.

4. Materials and Methods {#sec4-cancers-12-02049}
========================

The study group consisted of metastatic gastric cancer patients who received second-line systemic therapy with Ramucirumab 8 mg/kg (given on day 1 and 15) and Paclitaxel 80 mg/m^2^ (given on day 1, 8, and 15), both administered intravenously every 28 days. The cohort study was retrospective and performed among participating Institutions in the RAMoss analysis \[[@B31-cancers-12-02049]\], which retrospectively evaluated the safety and efficacy of Ramucirumab among Italian patients failing first-line treatment for advanced gastric cancer.

The control group comprised metastatic gastric cancer patients who underwent Cisplatin or Oxaliplatin plus 5-Fluorouracil systemic chemotherapy. This retrospective cohort was implemented from consecutive cases included in a large three-Institution database \[[@B32-cancers-12-02049]\]. In both cohorts, the study inclusion required the availability of primary tumor tissue samples. The study was performed in accordance with the reporting recommendations for tumor marker prognostic studies (REMARK) guidelines \[[@B33-cancers-12-02049]\]. All patient information and pathology materials were collected under a protocol approved by the Regional Ethical Committee (the protocol number is 2016-0374MN).

4.1. Samples and Nucleic Acids Extraction {#sec4dot1-cancers-12-02049}
-----------------------------------------

A sample of 4--6 10-μm sections from formalin-fixed, paraffin-embedded specimens were obtained from patient tumors and matched normal tissues. Before cutting sections for total nucleic acid isolation, an additional slide was prepared for hematoxylin-eosin staining and the pathologists identified representative areas with an almost complete representation of tumor infiltration. Tissues were micro-dissected and placed in a 1.5 mL reaction tube containing 1 mL xylene to remove paraffin. DNA was extracted using the RecoverAll^TM^ Multi-Sample RNA/DNA Isolation Workflow (Invitrogen^TM^ by Thermo Fisher, Foster City, CA, USA) according to the manufacturer's instructions. DNA concentration and purity were measured using the NanoDrop 1000 spectrophotometer (Nanodrop Technologies, Rockland, DE, USA).

4.2. Amplicons Library Preparation and Next-Generation Sequencing (NGS) for TP53 Analysis {#sec4dot2-cancers-12-02049}
-----------------------------------------------------------------------------------------

A custom panel (IAD_119861) including the *TP53* gene coding and UTR regions was designed using the Ion AmpliSeq™ Designer software (Thermo Fisher, Foster City, CA, USA). The panel was made up of 35 amplicons and ensured 82% of coverage for DNA from formalin-fixed paraffin-embedded (FFPE) tissues. Library preparation was performed using the Ion AmpliSeq Library Kit Plus according to the manufacturer's instructions. Libraries were generated using 40 ng of DNA from tumor FFPE sections and indexed using the Ion Xpress Barcode Adapter Kit. Library purification was carried out using the AMPure^TM^ XP Reagent (Beckman Coulter, Brea, CA, USA) on the DynaMag^TM^-2 Magnet. Qubit^TM^ 4 Fluorometer (Invitrogen^TM^, by Thermo Fisher, Foster City, CA, USA) was used to quantify amplicons libraries. After dilution of all samples at 100 pM, libraries were pooled for emulsion PCR on the Ion OneTouch™ 2 instrument, using the Ion S5™ Template OT2 kit, according to the manufacturer's instructions. The Ion Sphere™ Particles were enriched using the Ion OneTouch™ Enrichment System and the template was sequenced on the Ion Torrent S5 platform using the Ion 540^TM^ Chip (cat.no.A27766) following the manufacturer's instruction. All of these instruments and reagents were supplied by Thermo Fisher (Foster City, CA, USA). Read alignment was performed using hg19 (GRCh37) as the reference genome. Variant call files (VCF) were generated by the Variant Caller v.5 plugin preinstalled in the Torrent Suite and analyzed with the Ion Reporter™ software (Thermo Fisher, Foster City, CA, USA). BAM files were also manually checked on IGV (Integrative Genomics Viewer) \[[@B34-cancers-12-02049]\].

4.3. Classification of TP53 Mutations {#sec4dot3-cancers-12-02049}
-------------------------------------

Each *TP53* missense mutation was assigned a residual transcriptional activity score (*TP53~RTAS~*) according to the results of a site-directed mutagenesis technique and yeast-based functional assay \[[@B17-cancers-12-02049],[@B18-cancers-12-02049]\]. The *TP53~RTAS~* represents the median transcriptional activity value measured across eight different p53-responsive elements. Based on these functional scores, *TP53* missense mutations were then divided into two distinct groups: *TP53~RTAS~* ≥ 1% and *TP53~RTAS~* \< 1%. This categorization denotes a clear distinction between a transcriptionally inactive group (*TP53~Inactive~ =TP53~RTAS~* \< 1%) versus a transcriptionally active group (*TP53~Active~ =TP53~RTAS~* ≥ 1%). Carriers of non-missense mutations including nonsense and frameshift mutations were merged into a third mutational group.

4.4. VEGF and VEGFR Analyses {#sec4dot4-cancers-12-02049}
----------------------------

A gastric adenocarcinoma dataset was collected from the TCGA Pan-Cancer Atlas (<https://www.cancer.gov.tcga>) for the analysis of mRNA expression, copy number alterations, and mutational data of genes of interest. Tumors with *TP53* gene sequencing were selected and those with more than one *TP53* alteration were excluded. Individual tumors were then assigned a *TP53* mutation-specific RTAS, sub-grouped based on the RTAS, and analyzed for the gene expression and copy gain or loss of *VEGF-A*, *VEGF-C*, *VEGF-D*, and *VEGFR2*.

4.5. Statistical Analysis {#sec4dot5-cancers-12-02049}
-------------------------

The primary endpoint of the study was the overall survival (OS) analysis in carriers of *TP53~Inactive~* mutations in the Ramucirumab/Paclitaxel study group. With 40 events and a 20% prevalence of the *TP53~Inactive~* mutational status, the scenario for sample size estimation would allow detection of a 66% reduced risk of death with a power of 80% and a two-sided type I error of 5%. In the Ramucirumab/Paclitaxel group, OS was calculated from the date of the first cycle of the second-line therapy to the date of death or last follow-up. In the chemotherapy control group, OS was calculated from the date of the first cycle of the first-line therapy to the date of death or last follow-up. The Kaplan--Meier method was used to estimate survival curves and the log--rank test was used to compare survival times between groups. A multivariate Cox proportional hazards model was adopted for adjusting according to clinical and pathological features. Patients achieving complete response or partial response and patients with stable disease or disease progression were evaluated according to the RECIST criteria and the overall response rate included patients with a complete response and partial response. Contingency tables were analyzed by the Chi-square test. All reported *p*-values were two-sided, and confidence intervals (CIs) were at the 95% level. A *p*-value \<0.05 was considered statistically significant. Survival analyses were performed using MedCalc for Windows, version 15.0 (MedCalc Software, Ostend, Belgium). Data processing for the VEGF/VEGFR analyses in gastric cancer tissue was completed using R statistical environment version 3.6.2 and figures were generated using GraphPad Prism version 6.07.

5. Conclusions {#sec5-cancers-12-02049}
==============

The limitation of this study is the relative sample size, so our findings warrant further investigations to confirm the association between transcriptionally inactive *TP53* missense mutations and improved clinical outcomes of patients with metastatic gastric adenocarcinoma who received anti-VEGFR2 plus Paclitaxel systemic therapy. From a clinical perspective, the *TP53~RTAS~* mutational analysis might improve the identification of patients who are likely to have the greatest benefit from Ramucirumab therapy. Ramucirumab and chemotherapy failed to achieve significant survival advantages in a randomized phase III study when adopted as a first-line therapy for metastatic gastric cancer \[[@B35-cancers-12-02049]\]. In the overall treatment strategy for the metastatic disease, the selection of patients according to *TP53~RTAS~* mutational status represents a promising model to tailor treatment choices and improve clinical outcomes. In addition, *TP53~RTAS~* analysis could be evaluated in patients with metastatic adenocarcinomas in other solid tumors with frequent *TP53* mutations and where anti-VEGF therapy is commonly employed.
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![Plots of vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) analysis in gastric cancer tissues. Data were collected from the TCGA PanCancer Atlas. \* indicates statistically significant differences between groups as described in the text.](cancers-12-02049-g004){#cancers-12-02049-f004}

cancers-12-02049-t001_Table 1

###### 

Description of the tumor protein p53 (*TP53*) mutations detected in 70 patients.

  Mutation                  Amino Acid Change   Effect               RTAS    Functional Classification   Hg19 Coordinates   Therapy Group
  ------------------------- ------------------- -------------------- ------- --------------------------- ------------------ ---------------
  G \> T                    G245C               missense mutation    0       Inactive                    7577548            R/P-SC
  G \> A                    M246I               missense mutation    0       Inactive                    7577543            R/P
  C \> T                    R248W               missense mutation    0       Inactive                    7577539            R/P-SC
  C \> T                    R282W               missense mutation    0       Inactive                    7577094            R/P ^2^-SC
  G \> A                    R283H               missense mutation    0       Inactive                    7577090            R/P ^3^
  C \> T                    T304I               missense mutation    0       Inactive                    7577027            R/P-SC
  G \> A                    G244D               missense mutation    0.2     Inactive                    7577550            R/P-SC ^2^
  C \> T                    R273C               missense mutation    0.4     Inactive                    7577121            SC3 ^5^
  G \> A                    V216M               missense mutation    1.2     Active                      7578203            SC
  C \> T                    P151S               missense mutation    5.2     Active                      7578479            SC
  G \> A                    R175H               missense mutation    9.2     Active                      7578406            R/P-SC
  T \> C                    I195T               missense mutation    11.4    Active                      7578265            SC
  C \> G                    P177R               missense mutation    12.0    Active                      7578400            R/P
  C \> T                    L194F               missense mutation    12.0    Active                      7578269            SC
  C \> T                    S260F               missense mutation    12.6    Active                      7577502            SC
  G \> A                    G105S               missense mutation    15.0    Active                      7579374            SC
  C \> T                    H214Y               missense mutation    20.9    Active                      7578209            SC
  C \> T                    H179Y               missense mutation    22      Active                      7578395            R/P
  G \> A                    E180K               missense mutation    22.8    Active                      7578392            R/P
  C \> T                    P177S               missense mutation    26.9    Active                      7578401            SC
  G \> A                    R282Q               missense mutation    30.5    Active                      7577093            R/P
  C \> T                    P190S               missense mutation    32.0    Active                      7578281            SC
  C \> T                    R181C               missense mutation    32.4    Active                      7578389            R/P
  G \> A                    D228N               missense mutation    40.7    Active                      7577599            SC
  G \> A                    C229Y               missense mutation    69.3    Active                      7577595            SC
  C \> T                    R175C               missense mutation    72.5    Active                      7578407            R/P
  C \> T                    L252F               missense mutation    76.7    Active                      7577527            SC
  G \> A                    R379H               missense mutation    77.8    Active                      7572974            SC
  C \> T                    H115Y               missense mutation    81.1    Active                      7679344            R/P
  G \> A                    G356R               missense mutation    88.3    Active                      7573961            SC
  C \> T                    S116F               missense mutation    90.7    Active                      7579340            SC
  G \> A                    V225I               missense mutation    91.7    Active                      7577608            R/P
  G \> A                    A353T               missense mutation    96.9    Active                      7573970            SC
  C \> T                    L383F               missense mutation    97.5    Active                      7572962            R/P
  C \> T                    S90F                missense mutation    99.2    Active                      7579418            SC
  G \> A                    R174K               missense mutation    102.0   Active                      7578409            SC
  C \> T                    P222L               missense mutation    102.9   Active                      7578184            R/P
  G \> A                    E294K               missense mutation    107.7   Active                      7577058            SC
  G \> A                    S261N               missense mutation    108.0   Active                      7577499            SC
  C \> T                    S314F               missense mutation    110.0   Active                      7576905            SC
  G \> A                    V217M               missense mutation    116.0   Active                      7578200            SC
  G \> A                    G226D               missense mutation    120.1   Active                      7577604            R/P
  C \> T                    R290C               missense mutation    134.2   Active                      7577070            SC
  C \> T                    T329I               missense mutation    138.6   Active                      7576860            SC
  C \> T                    T312I               missense mutation    139.8   Active                      7576911            R/P
  G \> A                    A307T               missense mutation    142.7   Active                      7577019            SC
  C \> T                    P309S               missense mutation    151.2   Active                      7576920            R/P
  C \> T                    R196 \*             nonsense mutation    \-      Other                       7578263            SC
  C \> T                    Q192 \*             nonsense mutation    \-      Other                       7578275            SC
  C \> T                    R342 \*             nonsense mutation    \-      Other                       7574003            R/P
  C \> T                    Q317 \*             nonsense mutation    \-      Other                       7576897            SC
  C \> T                    R306 \*             nonsense mutation    \-      Other                       7577002            R/P
  C \> T                    Q165 \*             nonsense mutation    \-      Other                       7578437            SC
  C \> G                    Y107 \*             nonsense mutation    \-      Other                       7579366            R/P
  GTC \> GT                 L93X                reading frameshift   \-      Other                       7579408            R/P
  tGCCCCCac \> tTCCCCCCac   CPH176-178FPPX      reading frameshift   \-      Other                       7578397-403        SC
  GCCCCCTCC \> gCCCCTCcc    APS88-90VPS         reading frameshift   \-      Other                       7579419-424        R/P
  AGA \> A                  R209X               reading frameshift   \-      Other                       7578221-223        SC
  CCT \> -                  P190-               inframe deletion     \-      Other                       75782780-281       R/P
  G \> T                    \-                  acceptor intron 8    \-      Other                       7576927            R/P
  G \> A                    \-                  acceptor intron 9    \-      Other                       7576852            SC

Abbreviations: RTAS, residual transcriptional activity score; SC, standard chemotherapy; R/P, Ramucirumab/Paclitaxel; hg19, Genome Reference Consortium Human Build 37 (GRCh37) coordinates; Legend: ^2^ mutation in two cases; ^3^ mutation in three cases; ^5^ mutation in five cases; \* stop codon.
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###### 

Characteristics and distribution of the 110 patients according to treatments and *TP53* status.

  Number of Patients (%)                                                                           
  ------------------------ ----------- ----------- ----------- ----------- ----------- ----------- ------
                           TP53 wt     TP53 mut    TP53 wt     TP53 mut    TP53 wt     TP53 mut    
  Age                                                                                              
  \>65 years               12 (63.2)   15 (51.7)   11 (52.4)   20 (48.8)   23 (57.5)   35 (50)     0.5
  ≤65 years                7 (36.8)    14 (48.3)   10 (47.6)   21 (51.2)   17 (42.5)   35 (50)     
  Gender                                                                                           
  Male                     11 (57.9)   16 (55.2)   15 (71.4)   23 (56.1)   26 (65)     39 (55.7)   0.4
  Female                   8 (42.1)    13 (44.8)   6 (28.6)    18 (43.9)   14 (35)     31 (44.3)   
  Grading                                                                                          
  1--2                     16 (84.2)   20 (68.9)   14 (66.6)   24 (58.5)   30 (75)     44 (62.8)   0.2
  3                        3 (15.8)    9 (31.1)    7 (33.4)    17 (41.5)   10 (25)     26 (37.2)   
  Peritoneum involvement                                                                           
  Positive                 10 (52.6)   16 (55.2)   3 (14.3)    14 (34.2)   13 (42.5)   30 (42.8)   0.4
  Negative                 9 (47.4)    13 (44.8)   18 (85.7)   27 (65.8)   27 (67.5)   40 (57.2)   
  ECOG PS                                                                                          
  0                        9 (47.3)    18 (62.1)   18 (85.7)   24 (58.5)   27 (67.5)   42 (60)     0.5
  1--2                     10 (52.7)   11 (37.9)   3 (14.3)    17 (41.5)   13 (42.5)   28 (40)     
  Lauren's histology                                                                               
  Intestinal               12 (63.2)   23 (79.3)   11 (52.4)   32 (78)     23 (57.6)   55 (78.5)   0.02
  Diffuse                  7 (36.8)    6 (20.7)    10 (47.6)   9 (22)      17 (42.5)   15 (21.5)   
  Grading                                                                                          
  1--2                     10 (52.6)   19 (65.5)   12 (57.1)   31 (75.6)   22 (55)     50 (71.4)   0.09
  3                        9 (47.4)    10 (34.5)   9 (42.9)    10 (24.4)   18 (45)     20 (28.6)   
  Primary tumor resected                                                                           
  Yes                      12 (63.2)   9 (31.1)    10 (52.4)   18 (43.9)   22 (55)     27 (38.5)   0.1
  No                       7 (36.8)    20 (68.9)   11 (47.6)   23 (56.1)   18 (45)     43 (61.5)   
  Primary tumor site                                                                               
  Cardia                   7 (36.8)    11 (37.9)   9 (42.9)    15 (36.5)   16 (40)     26 (37.1)   0.8
  non-cardia               12 (63.2)   18 (62.1)   12 (57.1)   26 (63.5)   24 (60)     44 (62.9)   
                                                                                                   

Abbreviations: wt, wild-type; mut, mutated; ECOG PS, Eastern Cooperative Group Performance Status.
